Related Experiment Video
Updated: Oct 14, 2025

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Obesity and Nonalcoholic Fatty Liver Disease
1Department of Transplant, Mayo Clinic College of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Abstract:
Obesity and nonalcoholic fatty liver disease (NAFLD) have a significant global impact, and their complications are quickly becoming a reason for primary care visits and hospitalizations. This article provides an overview of NAFLD and obesity, pathogenesis of NAFLD and nonalcoholic steatohepatitis, clinical presentation and diagnostic criteria, and a review of practice guidelines. The current mainstay of treatment for NAFLD are lifestyle modifications and include a plan to eat, move, and change behavior. The future holds potential for new drug therapies in treating NAFLD. More research is needed to move these treatments forward.
More Related Videos
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Drug Dosing: Obese Patients